Based on the observation that children with a history of atopic disease show significantly increased levels of cleaved secretory IgA in nasopharyngeal secretions, wc have previously formulated the hypothesis that bacteria-induced local deficiencies of the immune barrier of the upper respiratory tract may be a contributing factor in the development and perpetuation of atopic diseases. To evaluate this hypothesis, 25 infants were subjected to clinical, bacteriologic, and immunologic examination at the age of 18 mo, 30 mo, and 5 y. The 11 infants, who showed clinical and immunologic evidence of atopic disease at the age of 18 mo, harbored significantly higher proportions of IgAl protease-producing bacteria (median, 36%; range, 14-64%) than the 14 healthy infants (median, 5%; range. 0.4-14%). No statistically significant differences were observed at the two subsequent examinations, but healthy children showed a statistically significant increase in proportions of IgAl protease-producing bacteria in the pharynx with increasing age. IgAl proteaseThe mucosal membranes of the upper respiratory tract are among the most important surfaces through which sensitizing allergens pass. The principal mediator of specific humoral immunity at mucosal membranes of the body, including the upper respiratory tract, is S-IgA. Besides protecting the surfaces against infectious agents, S-IgA is capable of inhibiting the penetration of macromolecular antigens including potential allergens across mucosal membranes (1, 2). Clinical evidence for this function includes the demonstrated association of atopic disease with permanent or transient IgA deficiency (3-6).
The mucosal membranes of the upper respiratory tract are among the most important surfaces through which sensitizing allergens pass. The principal mediator of specific humoral immunity at mucosal membranes of the body, including the upper respiratory tract, is S-IgA. Besides protecting the surfaces against infectious agents, S-IgA is capable of inhibiting the penetration of macromolecular antigens including potential allergens across mucosal membranes (1, 2). Clinical evidence for this function includes the demonstrated association of atopic disease with permanent or transient IgA deficiency (3-6).
S-IgA in the upper respiratory tract consists almost exclusively of the IgAl subclass (7) which is susceptible to bacterial IgAl proteases that specifically cleave the heavy chain of IgAl Received April 76. 1904 : accepted February 1-4, 1995 producing bacteria detected included Streptococcus mitis biovar
Haenzophil~ls influenzne, Haemophilu.~ parahaemolyticlrs,
Streptococc~rs pr~e~cnzonziae, and Neisseria meningitidis, of which the first mentioned species was mainly responsible for the difference observed at the 18-mo examination. Percentage proportions of IgAl protease-producing bacteria were significantly related to passive smoking which may stimulate the premature and more pronounced pharyngeal colonization of the atopic infants with the IgAl protease-producing variant of S. rnitis biovar I. The results of the study support the hypothesis that IgAl protease-producing bacteria colonizing the upper respiratory tract jeopardize the local immune barrier and, thereby, may facilitate the penetration of potential allergens resulting in atopic disease. (8) (9) (10) (11) (12) . W e have previously examined the degree of IgAI protease-induced cleavage of S-IgA in nasopharyngeal secretions of a group of children. Among 9 7 children (age 2.6-5.7 y) characteristic cleavage fragments of S-IgA1, i.e.
monomeric Fab fragments and dimeric Fc fragments associated with the secretory component (Fc,.SC) , were demonstrated at a significantly higher prevalence (61.5% versiis 11.9%) in secretions from atopic children than in healthy controls (13, 14) . On this basis we presented the hypothesis that a local functional deficiency in the immune. barrier of the upper respi- y of age designed to evaluate this hypothesis.
METHODS

Study population.
The study included 25 infants who were part of a population study of cord blood IgE and the development of atopic disease (15). From a birth cohort of 1625 infants born at the University Hospital of Odense, Denmark, 196 infants had a cord blood IgE concentration of 20.5 kU1L. These 196 infants were followed clinically together with 242 control infants with IgE levels within the normal range ( 5 0 . 3 kU/L). The 25 infants included in this study were the first of each of the two groups seen in the morning at the out-patient clinic at the 18-mo examination. Twelve of the infants had a family history of atopic disease (one or both parents having atopic disease) and a cord blood IgE level of 20.5 kU/L. The remaining 13 infants had cord blood IgE levels of 1 0 . 3 kU/L and no family history of atopic disease. All 25 infants were followed for 18 mo, 23 of these for a further 12 mo, and 20 for a total of 5 y. Informed consent was obtained from parents of the infants included in the study, and the study protocol was approved by the regional Ethics Committee for Scientific Research.
Clinical examination. At the age of 18 mo, 30 mo, and 5 y the children visited the out-patient clinic. They underwent a physical examination, and a complete history was taken with emphasis on atopic disposition, diet, housing, pets, smoking habits of the parents, atopy in the family, and infections. Atopic disease was defined as one or more of the following clinical symptoms: 1) bronchial asthma; 2) atopic dermatitis (areas of scaly, erythematous, and itchy eczematous rash with atopic localization); 3) two or more episodes of urticaria of known origin; and 4) two or more episodes of gastrointestinal allergy or intolerance to specific foods with at least one, objectively verified, positive food challenge. These criteria are identical to those used by van Asperen et al. (5) and Croner et al. (16) except that, relative to the former (5), nonimmediate food reactions were included in our study.
Immunologic examination. Blood samples for IgE determination and radioallergosorbent test for several allergens were taken if the parents permitted this at the age of 18 mo and 5 y.
Bacteriologic examinations. A throat swap collected with a coal-impregnated cotton swab from the posterior oropharyngeal wall of each child was transported to the bacteriologic laboratory in modified Stuart's transport medium (Statens Seruminstitut, Copenhagen, Denmark). Within 24 h of collection the swab was transferred to 3 mL of cold brain heart infusion broth (Difco, Detroit, MI), and the sample was suspended using a Whirly mixer for 10 s. Aliquots of 0.1 mL of appropriate 10-fold dilutions in cold brain heart infusion broth were spread with a sterile bent glass rod on duplicate sets of blood agar and on heated blood (chocolate) agar plates containing 300 mg of bacitracinll. The inoculated agar plates were incubated for 2 d in an atmosphere of air plus 5% carbon dioxide.
The total number of colony forming units in the sample was calculated on the basis of colonies counted on agar plates with from 30 to 300 colonies and taking the dilution factor into account. The relative proportion of Haernophilus species in each sample was calculated on the basis of the number of Haernophilus colonies growing on the selective chocolate agar relative to the total number of colonies growing on the -nonselective blood agar taking the respective dilution factors into account.
From each of one selected blood agar and chocolate agar plate culture of each sample 50 colonies were subcultivated to purity, and each culture was examined for IgAl protease activity by immunoelectrophoresis, using purified myeloma IgAl as substrate as described previously (10). Isolates showing IgAl protease activity were finally identified using standard techniques (17) (18) (19) .
Statistical analysis. Comparison between groups was performed with nonparametrical, two-tailed Mann-Whitney U test and comparisons between several groups with the Friedman test. Fischer's exact test was used for statistical evaluation of 4-fold tables, and the Spearman test was used for correlation analyses.
RESULTS
Clinical results.
Of the 25 infants examined, 11 satisfied the clinical and immunologic criteria for having atopic disease at the 18-mo examination. Several of the 11 infants showed multiple clinical signs of atopy (Table 1) . Among the 11 atopic infants six had shown significantly raised levels of IgE (20.5 kUIL) in cord blood. The remaining five atopic infants showed IgE levels in cord blood of <0.1-0.1 kU/L (Table 1) . Two of the atopic infants (subjects 4 and 5) experienced recurrent gastrointestinal and upper respiratory tract infections, respectively, in addition to signs of atopy. One of the nonallergic infants (subject 15) suffered from recurrent middle ear infections. Atopic disease at the 18-mo examination was significantly correlated with passive smoking ( p = 0.0051; 4-fold table).
At the 30-mo examination eight of the 23 children examined showed clinical signs of atopic disease. Two of the eight children with atopy at the 30-mo examination (subjects 20 and 24) had shown increased IgE levels in cord blood (1.3 and 1.4 kU/L) but revealed no clinical sign of atopic disease at the 18-mo examination. At the 5-y examination only three of the 20 children examined fulfilled the criteria for having atopic disease.
Bacteriologic findings. The total bacterial counts in the samples calculated on the basis of colonies growing on the nonselective blood agar were in the range of approximately 10' to 5 X lo6. The corresponding Haernoplzilus counts, including all Haemophilus species, calculated on the basis of growth on the selective chocolate agar, ranged from undetected (no growth from undiluted sample suspension) to 3 X lo6. H. influenzae constituted from 0 to 23% (median, <I%) of the bacterial flora at the 18-mo examination, from 0 to 95% (median, 1.7%) at the 30-mo examination, and from 0 to 63% (median, <I%) at the 5-y examination.
ZgAZ protease activity and atopic dzsease. Approximately 5 500 bacterial isolates were examined for IgAl protease activity. The relative proportion of the cultivable oropharyngeal bacterial flora in each subject at each of the three examinations that possessed IgAl protease activity is shown in Table 1 . In infants 18 mo of age without signs of atopic disease a median proportion of 5% (range, 0.4-14.0%) of the nasopharyngeal bacteria showed IgAl protease activity. The proportions were significantly higher ( p < 0.0005) in infants with atopic disease (median, 36%; range, 14-64%) (Fig. 1) . The two children who developed atopy between the first and second examination and had increased IgE levels in cord blood showed low levels of IgAl-producing bacteria at the 18-1110 examination. At the 30-1110 examination the proportion of IgAl protease-producing bacteria in the pharyngeal flora of the eight children with atopy (median, 22%; range, 2-64%) was similar to those found in the 15 nonatopic children (median, 20%; range, 0-95%). At the 5-y examination only three children were atopic. Consequently, no statistical analysis of the data from the 5-y examination was performed. A comparison of the figures for the healthy children at 18 mo, 30 mo, and 5 y of age revealed a statistically significant significant increase ( p = 0.00166) in the proportion of pharyngeal bacteria that had IgAl protease activity with increasing age. The same pattern was not observed in the atopic children who had high initial levels of IgAl protease-producing bacteria. Analysis of the of the IgE levels in cord blood and proportions of IgAl protease-producing bacteria at the 18-mo examination by the Spearman test revealed no significant correlation between the two parameters.
All isolates with IgAl protease activity were subsequently identified to species level. Table 2 summarizes the findings for the 18-mo examination. S. mitis biovar 1 constituted the majority of the bacteria with IgAl protease activity. Only in three children (subjects 8, 9, and 11) with atopic disease did H. injuenzue and N. meningitidis contribute significantly to the group of IgAl proteasc producers observed during the study. Among the 15 children who were found to be nonatopic at the 30-mo examination, five carried high levels of IgAl proteaseproducing bacteria (62-95% of the flora), whereas the remaining showed relatively low levels (median 10%; range 0-23%).
In three of the children with high levels, H. injuenzue accounted for the majority of the observed protease producers (98 out of 98%, 95 out of 95%, and 55 out of 62%). In contrast, in the children with low proportions of IgAl protease-producers, S. mitis biovar 1 predominated, whereas H. injuenzae constituted a minor part of the flora (0-17%). Other IgAl protease-producing species were found in insignificant numbers (data not shown).
ZgAl protease activity and passive smoking. Fifteen of the 25 infants included in the study were exposed to passive smoking in their respective homes (Table 1) . There was a strong association between passive smoking and increased levels of IgAl protease-producing bacteria in the pharyngeal microflora at the 18-1110 examination ( p = 0.0028). The median proportions of IgAl protease-producing bacteria in the pharynx of the passive smokers and nonsmokers were 26% (range 2-64%) and 4% (range 0.4-31%), respectively.
DISCUSSION
The concept that development of atopic disease may be associated with IgA deficiency is based on three lines of evidence. First, IgA deficiency results in increased penetration of intact macromolecules through mucosal membranes (1, 21). Second, an increased prevalence of IgA deficiency or reduced levels of S-IgA in nasal secretions has been observed in atopic subjects (3, 6), and third, comparatively low levels, yet within normal range, of serum IgA was found in atopic infants (4, 20) . In line with these observations van Asperen et al. (5) found an increased prevalence of reduced levels or absence of salivary IgA in infants up to 20 mo of age and born to atopic parents compared with controls. Studies in older children (5, 22, 23) and adults (24) have failed to demonstrate differences in S-IgA levels between atopic and nonatopic subjects. Collectively, these studies suggest that the determining difference with regard to lack of or reduced IgA-mediated mucosal protection against sensitization occurs early in life. Our demonstration of significantly increased proportions of IgAl protease-producing bacteria in the oropharynx of atopic children at the 18-mo examination compared with healthy controls, but not at later examinations, is in agreement with this notion. These bacteriologic results corroborate our previous demonstration of a significantly increased prevalence of extensive cleavage of S-IgA in nasopharyngeal secretions of atopic children resulting in virtual absence of intact, functionally competent IgA molecules and, thus, in an impaired immune barrier (13, 14) . Although the ensuing break in the immune barrier is restricted to the upper respiratory tract, the facilitated penetration of potential allergens may conceivably result in hypersensitivity reactions at distant sites such as the gastrointestinal canal and the skin, which is in agreement with the variety of clinical signs of atopy observed in this study. However, it cannot be excluded that IgAl proteases of bacteria swallowed from the upper respiratory tract exert a direct effect on IgAl in the gastrointestinal canal.
An important question is whether the presence of IgAl protease-producing bacteria and the ensuing local deficiency of functional S-IgA is a contributing cause of the development and perpetuation of the atopic condition in the infants or merely is a secondary event. Increased occurred of Staphylococcus aureus and P-hemolytic streptococci on the skin of atopic dermatitis patients has been noted (25), and an association between development of atopy and respiratory virus infection has been suggested (26, 27) . Theoretically, an increased prevalence of potential pathogens such as H. injuenzae, S. pneumoniae, and N. meningitidis, which produce IgAl protease, might reflect an increased infection susceptibility associated with but not causing the atopic condition. However, none of these potential respiratory pathogens, which produce IgAl protease, was found at higher prevalences in the atopic children. Surprisingly, the IgAl protease-producing species that accounted for the significant difference between the two groups was S. mitis biovar 1 which occurs in a proteaseproducing and a nonproducing variety (12, 19) . Both are commensals of the oral cavity from infancy and, to a lesser extent, the oropharynx of adults (28,29), and there is no reason to suspect that either is a respiratory pathogen.
Rather than reflecting a lifelong difference in the ability to become colonized by the IgAl protease-producing variety of S. mitis biovar 1, our data indicate a premature predominance of this species in the pharynx of infants developing atopic disease. The reason for this unexpected finding is unknown. Passive smoking may be a contributing factor. Our data revealed a strong association between passive smoking and increased proportions of IgAl protease-producing bacteria. Although smoking merely may be a confounding factor, it has been previously shown that tobacco smoke components may have a selective toxic effect on particular species inhabiting the respiratory tract (30, 31) . In vitro studies have indicated that S. mitis and other viridans streptococci are less susceptible to the harmful effects of cigarette smoke than several Gram-negative species (32). Clinically, several studies have demonstrated an association between passive tobacco smoking and development of asthma and atopic disease (33-35). 
